Menu

Investors

Dune Medical Devices strives to improve the standard of care for cancer patients every single day. With a first indication in breast cancer, our proprietary radiofrequency spectroscopy platform has been utilized in over 10,000 patients. Our first device, MarginProbe, has been shown to reduce re-excision rates in lumpectomy surgery by 62%.

And we are not stopping there. Our RF platform based biopsy device is currently in development thanks in part to a $3 million EC Horizon 2020 grant.

If you would like to know more about our business and its potential, contact info@dunemedical.com.

Contact Us

×
X
- Enter Your Location -
- or -
Search